Good day, and welcome to the 2024 Phathom Pharmaceuticals Annual Stockholders Meeting. I would now like to turn the meeting over to Phathom's President and Chief Executive Officer, Terrie Curran. Ms. Curran, please go ahead.
Good morning, and welcome to the 2024 Annual Stockholders Meeting of Phathom Pharmaceuticals. I am Terrie Curran, President and Chief Executive Officer at Phathom. It's my pleasure to welcome you here today for our Annual Stockholders Meeting and to introduce the Chairman of Phathom Board of Directors, Michael Cola.
Thank you, Terrie, and welcome, everyone. Thank you for joining us today for our virtual 2024 Stockholders Meeting. As is our custom, we will conduct the business portion of our meeting first and answer questions at the end of the meeting. Any unanswered questions will be addressed on the investor relations section of our corporate website following the meeting. To help us conduct an orderly meeting, we ask that stockholders abide by the rules of conduct available through the link on the webcast screen. It is now shortly after 10 A.M. Eastern Time, May 23rd, and this meeting is officially called to order. In light of the virtual meeting format, the polls are open, and stockholders can vote by clicking on the Vote Here button on the bottom of the webcast screen. Members of Phathom's Board of Directors are attending today's meeting through this webcast.
Also attending through the webcast are members of Phathom's senior management team and representatives of Ernst & Young LLP, the company's registered public accountant. Now it's my pleasure to introduce Phathom's Corporate Secretary, Bill Aprea. Bill will act as secretary of the meeting and will discuss some procedural matters with you. Bill?
Thank you, Mike. Please note that this meeting is being recorded and will be available for replay at www.virtualstockholdermeeting.com/phathom2024. Even though we are providing a replay, no one attending via the webcast is permitted to use any audio recording device. Finally, the company has appointed me to act as Inspector of Election. On May 16, 2024, I took the oath of Inspector of Election. The agenda and the rules of conduct are posted with the other meeting materials at the bottom of the webcast screen. The procedures we are following are simple and are designed to ensure that we have a fair and orderly meeting. As Mike explained, the polls are open. Many of you have already voted by proxy, and the proxy votes have been tallied.
If you want to vote now or change your vote, you can click on the Vote Here button at the bottom of the webcast screen. The polls will stay open until the conclusion of the review of the matter to be voted on. After the formal meeting has been adjourned, we will provide time for general questions. Only validated stockholders may ask questions in the designated field on the web portal. Your question will not be visible to other participants. Out of consideration for others, please limit yourself to one question. As I mentioned earlier, even though this meeting is being recorded, attendees are not permitted to use any audio recording device. This meeting is being held pursuant to proper notice.
58,524,101 shares of common stock were outstanding and entitled to vote at this meeting as of March 28, 2024, the record date of this meeting set by the Company's board of directors. Proxies representing a majority of these shares have been received, and therefore a quorum is present, and the meeting should proceed.
Thank you, Bill. We will now review the matters to be voted upon. Proposal one is the election of three Class II directors. The current board has nominated myself, Michael Cola, Frank Karbe, and Asit Parikh for election as directors to hold office until the 2027 Annual Meeting of Stockholders or until their successors are duly elected and qualified. Proposal two is the ratification of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024. Now that we have reviewed the matters to be voted on in the meeting, the polls for the 2024 Phathom Pharmaceuticals Annual Stockholders Meeting are closed. Bill, do we have a preliminary voting result?
We do. The preliminary vote shows that the nominees for election of the board have been duly elected, and the ratification of Ernst & Young LLP as the company's independent registered public accounting firm has received sufficient votes to be approved. We'll be reporting the final vote results in a Form 8-K to be filed within four business days.
Thank you, Bill. Now we would like to respond to stockholder questions. Please note, only questions that are germane to the meeting will be addressed. Questions not addressed at today's meeting will be addressed on the investor relations section of our corporate website after the meeting.
There are no stockholder questions to be addressed at today's meeting, Mike.
Excellent. There will be no further business to come before the meeting. The 2024 Annual Meeting of Stockholders of Phathom Pharmaceuticals is now adjourned. Thank you all for joining today.